PET scan imaging in oncology (Q35175450)

6 August 2017

1 reference

title

PET scan imaging in oncology (English)

1 reference

6 August 2017

Jerusalem G

1

1 reference

6 August 2017

Hustinx R

series ordinal

2

1 reference

6 August 2017

Beguin Y

series ordinal

3

1 reference

6 August 2017

Fillet G

series ordinal

4

1 reference

6 August 2017

publication date

1 July 2003

1 reference

European Journal of Cancer

6 August 2017

published in

1 reference

6 August 2017

volume

39

1 reference

6 August 2017

issue

11

1 reference

6 August 2017

page(s)

1525-1534

1 reference

The value of positron emission tomography (PET) imaging in disease staging and therapy assessment

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

CT colonography (virtual colonoscopy) for the detection of colorectal polyps and neoplasms. current status and future developments

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Functional computed tomography in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Functional ultrasound methods in oncological imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Functional MRI for anticancer therapy assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Gamma camera imaging in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

PET for in vivo pharmacokinetic and pharmacodynamic measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

PET imaging of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Application of positron emission tomography imaging to cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Analytical decision model for the cost-effective management of solitary pulmonary nodules.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using 18F-fluorodeoxyglucose: Diagnostic Limitations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Detection of unknown occult primary tumors using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

FDG-PET improves the management of patients with suspected recurrence of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

The role of positron emission tomography (PET) in the management of lymphoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcino

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Can positron emission tomography improve the quality of care for head-and-neck cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Positron emission tomography scanning in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Assessment of the technology for functional imaging in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900374-5

7 January 2021

10.1016/S0959-8049(03)00374-5

Identifiers

DOI

1 reference

6 August 2017

1 reference